Gyre Therapeutics (GYRE) EBIAT (2016 - 2025)
Historic EBIAT for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.
- Gyre Therapeutics' EBIAT rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 11412.47%. This contributed to the annual value of $17.9 million for FY2024, which is 12093.82% up from last year.
- According to the latest figures from Q3 2025, Gyre Therapeutics' EBIAT is $5.9 million, which was up 10784.31% from $1.6 million recorded in Q2 2025.
- Gyre Therapeutics' EBIAT's 5-year high stood at $51.6 million during Q2 2022, with a 5-year trough of -$101.0 million in Q4 2023.
- In the last 5 years, Gyre Therapeutics' EBIAT had a median value of $1.6 million in 2025 and averaged -$7.4 million.
- In the last 5 years, Gyre Therapeutics' EBIAT tumbled by 45361.46% in 2021 and then skyrocketed by 35909.27% in 2022.
- Over the past 5 years, Gyre Therapeutics' EBIAT (Quarter) stood at -$20.3 million in 2021, then plummeted by 37.23% to -$27.9 million in 2022, then crashed by 261.95% to -$101.0 million in 2023, then soared by 100.56% to $569000.0 in 2024, then soared by 943.23% to $5.9 million in 2025.
- Its EBIAT was $5.9 million in Q3 2025, compared to $1.6 million in Q2 2025 and $3.7 million in Q1 2025.